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DRAFT 
(please do not quote from this paper as it is a work in progress) 
 
Public Health Regulation: 
The Impact of Intersections between Trade & Investment Treaties in Asia 
 
Locknie Hsu 
 
 
I. Introduction 
 
As at 15 January 2012, the number of regional trade agreements (RTAs) notified 
to the WTO stood at 511.1  More specifically, according to the World Trade 
Report 2011 of the WTO, Asian WTO members are among the most active in 
signing preferential trade agreements.2 
 
Singapore, an early contributor to the current bilateral trade agreement trend, has 
signed ten bilateral free trade agreements (FTAs);3 Malaysia has signed bilateral 
six agreements;4 and China has already signed eight.5 All are in negotiations for 
further preferential trade agreements. Even Japan, a relative latecomer to the FTA 
“circuit”, has concluded 12 bilateral agreements.6 In addition to such bilateral 
agreements, the ten countries in the Association of Southeast Asian Nations 
(ASEAN) have collectively signed regional preferential trade agreements with 
external trading partners such as China, India, Japan, Korea, and Australia and 
New Zealand. 
 
FTAs typically cover a wide range of issues and areas of trade and investment, 
providing for both improved access and protection as well as new or strengthened 
commitments not made in other fora (such as the WTO). As a result, public health 
regulation – as well as any other areas of regulation - has been significantly 
affected by such treaties. They contain significant legal commitments that alter 
the regulatory flexibility of signatory states, particularly in relation to goods, 
services and investments that have a bearing on the protection and promotion of 
human life and health. Private enterprises are active in providing input for 
negotiating such agreements to canvass for greater protection than what may be 
                                                 
  Associate Professor, School of Law, Singapore Management University; email: 
lockniehsu@smu.edu.sg. 
1  See WTO website at: http://www.wto.org/english/tratop_e/region_e/region_e.htm.  
2  See the report at the WTO website at: 
http://www.wto.org/english/res_e/publications_e/wtr11_e.htm.  
3  See Singapore Ministry of Trade and Industry website at: 
http://www.fta.gov.sg/fta_ongoingneg.asp and http://www.fta.gov.sg/fta_concluded.asp. 
4  See Malaysia Ministry of International Trade and Industry website at: 
http://www.miti.gov.my/cms/content.jsp?id=com.tms.cms.section.Section_8ab55693-7f000010-
72f772f7-46d4f042.  
5  See China Ministry of Commerce website at: http://fta.mofcom.gov.cn/english/fta_qianshu.shtml.  
6  See Japan Ministry of Foreign Affairs website at: http://www.mofa.go.jp/policy/economy/fta/.  
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required under existing WTO obligations and domestic law.7 Countries pursuing 
bilateral and regional trade and investment agreements need to balance the 
expectations of such companies which may both be exporters as well as investors 
in the field of pharmaceutical products, against public health concerns and needs 
of the country. 
 
Bilateral treaties may commit states to obligations surpassing those in the WTO 
TRIPS Agreement (i.e., “TRIPS-plus” commitments), resulting in significant 
curtailment or reduction of regulatory rights in relation to health. While not all 
FTAs of Asian states contain such extensive obligations, Singapore and Korea are 
examples of Asian countries that have entered bilateral FTAs contain binding 
“TRIPS-plus” commitments. While such agreements usually also contain some 
exceptions relating to the protection of human health, such exceptions may not 
always apply to all commitments made. In addition, countries may also have 
made separate commitments in bilateral investment treaties (“BITs”), which often 
do not contain such exceptions. FTAs and BITs are becoming sources of 
intersecting state obligations pertaining to  trade, investment, intellectual property 
rights (IPRs) (such as in patents for pharmaceuticals) and the regulation of public 
health in Asian states. The true impact and effects of this intersection will become 
clearer in due course but it is easy to see that such impact can be far-reaching. 
 
While public health measures take many forms, this paper will examine the 
intersection of treaty obligations and public health regulation from two topical 
and critical angles: that of access to medicines and the regulation of tobacco-
related products, both of interest and concern to many Asian members of the 
WTO. 
 
Concerns and criticisms – including those over high prescription drug prices 
resulting from increasingly stringent patent and other IPR protection found in 
some FTAs - have already been raised in various countries. The current ‘mega’-
FTA, the Trans-Pacific Partnership Agreement (TPP) which is under negotiation 
among nine countries, is no exception to such criticism.8 
 
Measures relating to regulation of public health have so far not been challenged 
under any Asian FTA dispute settlement forum, it is not inconceivable that such a 
challenge may emerge in future. In 2010-2011, however, disputes demonstrating 
                                                 
7  See, for instance, the strong views provided by the US-ASEAN Business Council in relation to the 
USSFTA negotiations: www.us-asean.org/Singapore/comments_on_ussfta.doc.  
8  See for instance: http://www.ftamalaysia.org/article.php?aid=291. The TPP is currently under 
negotiation by Australia, Brunei Darussalam, Chile, Malaysia, New Zealand, Peru, Singapore, 
Vietnam, and the United States, with Canada and Mexico having just announced their plan to join 
them (see USTR statement, 19 June 2012: http://www.ustr.gov/about-us/press-office/press-
releases/2012/june/ustr-kirk-welcomes-canada-as-new-tpp-partner). Japan has indicated interest in 
possible participation. An open letter dated 8 May 2012 was signed by a number of academics, 
lawyers, former judges and other opinion-shapers, requesting the TPP negotiators to exclude 
investor-State arbitration, citing, inter alia, health regulation concerns; see 
http://tpplegal.wordpress.com/open-letter/.  
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the intersection of trade, investment and health measures arose in the form of 
challenges to national tobacco measures. In separate disputes and different fora, 
Uruguay and Australia are having their health-related, tobacco packaging laws 
challenged under their respective treaty obligations. These disputes have 
catapulted the health-trade-investment-IPRs intersection to the forefront of debate 
and are no doubt being watched keenly by Asian states that have similar BIT/FTA 
and WTO commitments, given their implications on health-related measures.9 
 
In addition, many FTAs carry commitments on SPS measures that could have a 
bearing on health regulation, equal to or stronger than those under WTO 
agreements.10 An example is the KORUS FTA, chapter 8, in which the Parties 
affirm their rights and obligations under the SPS Agreement of the WTO.11 
 
Apart from the above, the regulation of public health issues also intersects with 
the regulation of environmental issues which have a public health impact. For 
instance, while the KORUS FTA has separate chapters on IPRs (covering, inter 
alia, patents, pharmaceuticals and medical devices) and the Environment, the 
latter chapter explicitly recognizes the connection between environment 
regulatory measures and public health.12 
 
II.  Intersections 
 
A. Pharmaceuticals and FTAs 
 
                                                 
9  Health-related disputes have already been seen in the WTO dispute settlement system. A key 
recent example – in which the complainant was Indonesia - is the dispute in US – Measures 
Affecting the Production and Sale of Clove Cigarettes, WTO/DS406/AB/R, decision of the 
Appellate Body (22 March 2012), which examined health-related arguments and Art. XX(b) of the 
GATT 1994 in the context of complaints under the Agreement on Technical Barriers to Trade 
(TBT Agreement). For an overview of the interplay between trade and investment liberalization 
agreements and tobacco regulatory issues and disputes, see the very recent report by the World 
Health Organization, “Confronting the Tobacco Epidemic”, 2012, available at: 
http://whqlibdoc.who.int/publications/2012/9789241503723_eng.pdf. The report also discusses 
briefly the potential conflict between obligations in the Framework Convention on Tobacco 
Control (which many WTO members are signatories to) and those in trade and investment 
agreements (pp. 74-77). 
10  See for example Chapter 6 of the Malaysia-India Comprehensive Economic Cooperation 
Agreement; text available at: 
http://www.miti.gov.my/cms/documentstorage/com.tms.cms.document.Document_b3c9637d-
c0a8156f-5df15df1-d75dff43/MICECA%20-%20edit%20as%20at%2003052011.pdf. 
11  However, that chapter has been excluded from the FTA dispute settlement process.Art. 8.4, 
KORUS FTA (the text of the chapter is available at: 
http://www.ustr.gov/sites/default/files/uploads/agreements/fta/korus/asset_upload_file267_12706.
pdf). The experience of the North American Free Trade Area (NAFTA) has shown that health-
related trade measures may form the subject of challenge under an FTA (note that the tribunal in 
that case found it lacked jurisdiction and did not proceed to hear the case): see the dispute on the 
US border closure to Canadian cattle, due to bovine spongiform encephalopathy (“BSE”, or “mad 
cow disease”) concerns: http://www.state.gov/s/l/c14683.htm.  
12  Art. 20.11, KORUS FTA.  
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Much of recent literature discusses the implications of provisions in FTAs that 
contain “TRIPS-plus” provisions, that is, bilateral treaty provisions that provide 
for commitments beyond and stronger than those that have been made in the 
WTO under the TRIPS Agreement. The trend of such TRIPS-plus provisions has 
frequently been examined in the context of enhancement and increased protection 
of rights of patent-holders, as compared with the wider public concern of ease of 
access to medicines that may be subject to such patents. 13  The stronger the 
protection, the more obstacles will be faced by competitors, especially those who 
manufacture generic drugs to treat similar diseases. 
 
An example of a concern that is the subject of ongoing debate is “evergreening”, 
in which pharmaceutical companies holding patents seek to “stretch” or enhance 
the available protection of their rights. This comprises various ways of 
expanding/extending protection by patent-holders of their rights, by essentially 
building on the existing patent. They can pose obstacles to manufacturers of 
generic medicines seeking to enter the market by blocking or delaying their 
market entry. 
 
Recent FTAs have reflected some of these practices giving increased patent-
holder protection in a number of ways. 
 
1. Patentability 
 
Some FTAs contain enhanced patentability provisions to the benefit of patent-
holders. The following illustrate this. 
 
a) Exclusions 
 
The USSFTA is an example of an FTA which reduces the scope of non-
patentable matter, as compared with TRIPS. Art. 16.7 provides for the Parties 
to exclude such inventions from patentability as are provided for in Arts. 27.2 
and 27.3(a) of the TRIPS Agreement. This therefore disallows them from 
excluding those inventions that are mentioned in Art. 27.3(b) of the TRIPS 
Agreement, so that there is no longer an option to exclude from domestic 
protection, plants, animals and biological processes originally within Art. 
27.3(b). This category has similarly been excluded from non-patentability 
under the USSFTA. 14  As a result, Singapore enacted the Plant Varieties 
Protection Act 2004.15 Other FTAs also require protection for plant varieties, 
such as the KORUS FTA16 and the EU-Korea FTA.17 
                                                 
13  For instance, for a discussion of Jordan’s position as an FTA partner of the United States and her 
TRIPS-plus commitments in relation to pharmaceutical trade under the US-Jordan FTA, see 
Bashar H Malkawi, March 2009 Vol 4 No 1 Asian J of WTO & Int’l Health Law and Policy, 95-
128. 
14  Art. 16.7.1, USSFTA. 
15  Cap. 232A, 2006 Rev. Ed. See generally, the CRS Congressional Research Report 2004 on the 
USSFTA and its IPR provisions: 
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b) Inclusions 
 
As part of patent-holders’ “evergreening” efforts to obtain further protection 
based on their existing patents, new uses or new methods of using, existing 
patented products such as patented pharmaceutical products, are claimed as 
new inventions meriting a new patent. While traditional patents formerly 
claimed rights over the original product or process, increasingly, 
pharmaceutical companies are claiming patents for such new uses or 
methods.18 
 
Art. 18.8(1) of the KORUS FTA provides a specific inclusion of new uses of a 
known product: 
 
“… each Party confirms that patents shall be available for any new uses or 
methods of using a known product.” (Italic emphasis added.) 
 
2. Patent Revocation, Oppositions and Renewals 
 
In an effort to preserve granted patents, some FTA provisions seek to limit the 
grounds for revocation once a patent is granted. 
 
Art. 18.4 of the KORUS FTA, for example, limts the grounds for revocation 
of a patent to those for refusal for grant. 
 
Art. 18.4 KORUS is an example.  Art. 18 also prevents the State Parties to the 
KORUS from providing for opposition to grant of patent before a grant is 
made. This is a hurdle to those who may wish to block the granting of a patent 
without merit. 
 
Some FTAs, such as Art. 10.35 of the EU-Korea FTA, provide for extensions 
of the duration of rights conferred by patents “to compensate the patent owner 
for the reduction in the effective patent life as a result of the first authorization 
to place the product on their respective markets”. 
 
3. Other Provisions 
 
a) Marketing Approval Processes and Data Protection 
 
                                                                                                                                                 
http://congressionalresearch.com/RL31789/document.php?study=The+U.S.-
Singapore+Free+Trade+Agreement. 
16  See Art. 18.8(2). 
17  See Art. 10.39 of the EU-Korea FTA. The full text of the FTA is available at: 
http://ec.europa.eu/trade/creating-opportunities/bilateral-relations/countries/korea/.  
18  See footnote 13, supra. 
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Art. 18.8(5) of the KORUS FTA requires that the use of “subject matter” of a 
patent should be for “generating information” to support an application for 
marketing approval, and any sale/export of goods using such “subject matter” 
should similarly only be for the purpose of supporting such an application. 
 
Art. 18.9 of the FTA, which applies in particular to “certain regulated 
products” and their patents, namely, pharmaceutical products and agricultural 
chemical products, provides periods of blockage of grant of marketing 
approval to other drug manufacturers. Besides such generous blockage periods, 
it is noteworthy that the protection terms and periods in Art. 18.9 KORUS 
exceed those of Art. 16.8.1-2 USSFTA.19 
 
Art. 16.8 of the USSFTA led to a new provision - section 19D - in the 
Singapore Medicines Act. Under this provision, where an earlier product 
licence has been granted with submission of safety and efficacy information 
for a medicinal product, no product licence is to be granted for the same 
product or a “similar” product on basis of the previous grant for a period of 5 
years from date of the first grant, unless the earlier licence holder consents.  
 
Art. 10.36 of the EU-Korea FTA similarly imposes a period of 5 years for the 
protection of data with respect to pharmaceutical products.20 
 
b) Patent Linkage Obligations 
 
As explained by one author: 
 
“’Patent linkage’ is a practice of linking regulatory approval for a generic 
medicine to the patent status of the originator product.”21 
 
While patent linkage exists in the patent legislation of some countries (such as 
Singapore and the US), other countries do not make such linkages. The EU for 
instance is such an example.22 
 
In the case of Singapore, the USSFTA came into force in 1 January 2004 and 
soon after, Singapore introduced amendments to its system of approval and 
                                                 
19  The USSFTA commitments by Singapore on data protection can be seen in s. 19A of the 
Medicines Act. See also saving clause in footnote 16-14 USSFTA. Note that Chapter Five of the 
KORUS FTA contains separate provisions on the sale and marketing of Pharmaceutical Products 
and Medical Devices. 
20  The full text of the EU-Korea FTA is available at: http://ec.europa.eu/trade/creating-
opportunities/bilateral-relations/countries/korea/.  
21  Hiroko Yamane, “Understanding TRIPS – Globalisation of Intellectual Property Rights and 
Access to Medicines”, Hart Publishing, 2011, at page 445. 
22  See EU Directive 2001/83/EC. 
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licensing of sale of medicines under the existing Medicines Act.23 One such 
amendment of some significance is section 12A which established patent 
linkage. 
 
The more recent KORUS FTA also imposes patent linkage obligations under 
Art. 18.8(5) and 18.9. Art. 18.9(4) further extends the period of protection 
against marketing approval in Art. 18.9(1)-(2) beyond the life of the patent in 
question. This means that upon the expiry of a patent during the period under 
those provisions, a generic manufacturer must still wait till the end of the 
protection period before a grant of approval can be obtained. 
 
 
c) Other Related FTA provisions 
 
Obligations on transparency of measures have been making an appearance in 
FTAs. These have the potential of affecting IPR-related measures and 
measures relating to marketing approval or licensing of pharmaceutical 
products. If these obligations are made subject to the FTA’s dispute settlement 
mechanism, transparency-related claims may arise. Examples include the 
general transparency provisions of Chapter 19 of the USSFTA and the more 
specific Art. 18.12 of the Intellectual Property Chapter of the KORUS FTA. 
 
 
d) Interface with Obligations in Chapter 11 Investment and Investor-State 
Dispute Settlement 
 
Companies that expend time and money on the development and marketing of 
pharmaceutical products would expect a reasonable return on that expenditure. 
IPRs such as patent rights arising from such efforts may form the subject 
matter of covered “investments” in an FTA. An example of an association of 
“investment” and the research and development behind valuable undisclosed 
data of patent holders is that made in relation to marketing approvals for 
generics. 24  Moreover, many FTAs explicitly list IPRs as covered 
“investments”. 
 
Expansion of the scope of patentable matter (as mentioned above), additional 
non-patent protection for enterprises holding patents by treaty (such as the 
protection of test data and the imposition of significant periods of blockage of 
marketing approval for other similar, generic products) and removal of pre-
grant opposition proceedings, all create new and additional obligations on the 
                                                 
23  Cap. 176. The amendments were introduced via the Medicines (Amendment) Act 2004 (No 26 of 
2004). Concomitantly, amendments were made to the Patents Act (Cap. 221) via the Patents 
(Amendment) Act 2004 (No 19 of 2004). 
24  See remarks in the Report by the Industry Trade Advisory Committee on Intellectual Property 
Rights (ITAC 15) at page 14, at: 
http://www.iipa.com/pdf/ITAC15FinalReportKoreaApril272007.pdf. 
© 22 June 2012, Locknie Hsu, Draft Paper for SIEL Conference 2012 
 
part of the host State. This in turn expands the area of liability and potential 
for complaints if such rights are in some way interfered with by that State. Yet, 
it may sometimes be necessary for a State to take certain measures to protect 
the health of its citizens, perhaps in a way that may impinge on these private 
enterprise rights. It is then not hard to imagine an investment-related 
complaint when an investor’s drug-related patent (or above-mentioned 
associated treaty rights) is seen to be affected in a manner prohibited the FTA. 
 
For example, most FTAs contain an assurance of “fair and equitable” 
treatment (FET) for investors and their covered investments. Given the width 
of this obligation (as demonstrated by several arbitral decisions), interference 
with an IPR may arguably be a breach of FET. Similarly, an argument may 
arise as to expropriation (which may include the potentially expansive notion 
of “indirect” expropriation). Such complaints may be brought by an investor 
in investor-State dispute settlement (such international arbitration) provided 
for under the FTA in question.25 As numerous prior investor-State arbitral 
decisions have shown, the ambit and interpretation of treaty provisions on 
which such complaints depend for success vary and outcomes are never 
totally predictable. In the case of FET obligations, while there have been a 
number of factors identified by such tribunals in determining if there has been 
a violation, their application and boundaries are not cast in concrete and could 
vary with the particular treaty language being interpreted.26 Should a violation 
of such a treaty obligation be found, significant compensation may be payable 
by the State. In addition, the State may have to review its measure to avoid 
further complaints or compensation. 
 
e) FTA Exceptions 
 
Some exceptions relating to measures to protect health exist under some FTAs. 
 
i. Explicit FTA Exceptions 
 
a. Investment exceptions 
 
There are some FTA provisions that provide a measure of protection to 
the State against complaints within the Investment Chapters 
themselves. An example is KORUS investment chapter Art. 11.8(3)(b). 
Another example is Art. 11.8(3)(c)(ii), in the same chapter, which 
contains an important exception on environmental measures that may 
be taken to protect human health. The Investment Chapter of the 
Malaysia-Australia FTA also provides a number of “General 
                                                 
25  Interestingly, a recent investor-State complaint initiated in 2012 is that of Apotex Holdings Inc and 
Apotex Inc v USA, in which the claimants are manufacturers of generic drugs, making claims 
under the investment provisions of NAFTA; see http://www.state.gov/s/l/c50826.htm. 
26  See for example the broad formulation of factors in TecMed v Mexico, ICSID Case No. ARB 
(AF)/00/2, (Award, 2003), and  
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Exceptions” in its Art. 12.18. It further provides in Art. 12.7.3 that a 
breach of another provision is not necessarily a breach of FET. 
 
In order to provide some regulatory flexibility with regard to public 
health, some FTAs contain an explicit exception for such measures in 
relation to the definition of “indirect expropriation”, such as Annex 
11-B, paragraph 3(b) exception, of the KORUS FTA. 
 
 
b. General exceptions 
 
While the number of FTA provisions that have an impact on trade and 
investment regulation in Asian countries has been increasing, there has 
been another – albeit less prominent and numerous increase in health-
related exceptions. 
 
FTAs often include general exception provisions, mirroring those in 
GATT and GATS, to permit, for example, measures necessary for the 
protection of “human, animal, or plant life or health”. An example is 
Art. 21.1 of the USSFTA. General exception provisions have been 
incorporated into investment chapters of some recent FTAs. An 
example of a general exception found in an FTA Investment Chapter is 
Art. 10.20 of the relatively recent Malaysia-India Comprehensive 
Economic Cooperation Agreement, which permits measures in the 
“public interest” including “measures to meet health, safety or 
environmental concerns” (subject to the conditions of that provision).  
In addition, Art. 12.1 extends the applicability of Art. XX GATT and 
Art. XIV GATS general exceptions to the investment chapter of that 
FTA. 
 
Art. 18.8(3) of the KORUS FTA permits “limited exceptions” the 
exclusive rights of a patent but subject to certain conditions stipulated 
in it. 
 
Another example is Art. 17(b) of the ASEAN Comprehensive 
Investment Agreement (ACIA), which came into force in March 2012.  
 
It is not known yet if the current TPP negotiations will produce a 
specific exception applying to tobacco-related measures. An 
announcement has however been made by the USTR of special 
consideration or a carve-out for tobacco regulation.27 While this matter 
remains under negotiation it is noteworthy that the TPP negotiating 
partners with regard to this issue (Brunei, Malaysia, New Zealand and 
Vietnam) have found it necessary to argue in favour of including some 
                                                 
27  Information about the draft proposal is available at: http://www.ustr.gov/about-us/press-
office/fact-sheets/2012/may/tpp-tobacco-proposal. 
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protection of regulatory powers over tobacco and tobacco-related 
products. 
 
iii. Recognition of WTO flexibilities 
 
 WTO members have chosen in some recent FTAs to include the 
specific flexibilities provided by the TRIPS Declaration on Public 
Health and related waivers and amendments. An example is KORUS 
Art. 18.9(3). 
 
 
B. FTAs, BITs and Tobacco 
 
Over the last two years, disputes have arisen between tobacco 
enterprises and States with regard to so-called “plain packaging” laws. 
These laws seek to regulate the packaging and appearance of tobacco 
products, and reflect aspirations and obligations arising from the World 
Health Organization-driven Framework Convention on Tobacco 
Control (FCTC).28 In respect of these laws, investor-State arbitration 
claims as well as constitutional claims in national courts have arisen.  
Uruguay is currently facing arbitration under the Swiss-Uruguay BIT, 
while Australia is facing challenges under the Hong Kong-Australia 
BIT, as well at the WTO. More recently, a tobacco enterprise initiated 
legal proceedings against Norway for her measures tightening sale and 
display of tobacco products. New Zealand has recently announced 
plans to introduce “plain packaging” laws for tobacco products as well, 
and already, there are indications that there may be legal challenges 
arising from this as well.29 
 
The significance of these disputes lies in the legal claims being made 
and the potential impact of rulings adverse to the states in question. 
The claims range from investment treaty obligations such “fair and 
equitable” treatment and expropriation, to TRIPS-related and 
Technical Barriers to Trade (TBT) complaints in the WTO system.30  
 
ICSID arbitral tribunals have shown in recent years a divergence in 
thinking in several important interpretative decisions, ranging from 
                                                 
28  The text of the FCTC and related information are available at: http://www.fctc.org/.  
29  See announcement by New Zealand’s Associate Minister for Health on 19 April 2012: 
http://www.loc.gov/lawweb/servlet/lloc_news?disp3_l205403106_text and 
http://business.scoop.co.nz/2012/04/19/moving-towards-plain-packaging-of-tobacco-products/; 
and press report of reactions at: http://www.odt.co.nz/news/national/206216/cigarette-pack-rules-
have-makers-fuming.  
30  Ukraine and Honduras have lodged complaints under the TRIPS Agreement and TBT Agreement 
against Australia: see http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds434_e.htm and 
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds435_e.htm respectively. The claims also 
include the “national treatment” provision in GATT 1994. 
© 22 June 2012, Locknie Hsu, Draft Paper for SIEL Conference 2012 
 
interpretation of the scope of the well-known FET obligation to what 
may or may not constitute compensable expropriation. 31  In some 
decisions, expansive interpretations have indeed been adopted, to the 
detriment of the state in question, resulting in findings of liability and 
orders for compensation that run into millions of dollars. 
 
The current disputes between tobacco companies and states such as 
Uruguay and Australia will provide valuable insight into as-yet 
untested provisions in the BITs and legal provisions in question, as 
disputes are decided in arbitration, national courts and at the WTO in 
the coming months. They will also shed light into the thinking of the 
respective tribunals on the intersection of IPR, trade, investment law 
and health issues within the context of the treaties in question. 
 
While there is currently a proposal to include tobacco in the TPP that is 
under negotiations and it remains to be seen what special 
considerations, if any, will emerge on TPP parties’ rights to protect 
public health.32 
 
 
III.  Conclusion 
 
The conclusion and negotiation of FTAs with strengthened IPR protection 
commitments by Asian states, juxtaposed with the fact that most FTAs 
also contain ISDS provisions, provide fertile ground for legal complaints 
arising from health-related measures. Examples troubling many policy-
makers are the issues relating to pharmaceutical and tobacco control 
measures. 
 
Existing TRIPS flexibilities are important to Asian developing states.33 
FTAs carrying TRIPS-plus obligations expand obligations of States and 
reduce those flexibilities in various forms. The fact that IPR obligations – 
including such TRIPS-plus ones – form treaty obligations and that IPRs 
are likely in most FTAs to be covered “investments” that are eligible for 
protection and to ISDS, lead to three key implications. First, TRIPS-plus 
                                                 
31  On the issue of divergences and developing fault lines in investor-State arbitration jurisprudence, 
see Locknie Hsu (2011), "Investment Treaty Disputes: Ideological Fault Lines and an Evolving 
Zeitgeist", December 2011, Vol. 12 No. 6, Journal of World Trade & Investment, 827-953. 
32  See the fact sheet made available recently, at:  http://www.ustr.gov/about-us/press-office/fact-
sheets/2012/may/tpp-tobacco-proposal.  
33   See for instance the views reflected at the Regional Consultation and Planning Workshop on “Use 
of TRIPS Flexibilities and Access to Affordable ARVs in Asia”, 29-31 May in Bangkok, Thailand: 
http://asia-pacific.undp.org/practices/hivaids/trips-flexibilities-workshop-may2012.html. See also 
UNDP/UNAIDS publication, UNDP, UNAIDS, “The Potential Impact of Free Trade Agreements 
on Public Health”, May 2012 (available at the same link as above). 
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obligations can curtail or significantly reduce a country’s regulatory 
flexibility with respect to health measures. A direct result can be the 
significant slowing down of generic products reaching a market, resulting 
in the maintenance of high prices of patented, prescription medicines.  
Secondly, health measures may be argued by investors who own affected 
IPRs – such as pharmaceutical patents – to be a failure by the State to 
observe its TRIPs-plus obligations. Finally, while such arguments are not 
guaranteed to succeed, the combination of trade, investment, IPRs, health 
and dispute settlement issues with availability of investment dispute 
settlement creates a strong temptation to test such arguments. Already, we 
are seeing this in the field of tobacco control measures, where arguments 
relating to IPR as well as investment law principles are being raised.  
 
Given the inherent uncertainties of interpretation arising from investment 
decisions and the novelty of challenges of this kind in the WTO, national 
courts and in investment arbitration, the regulation of health continues to 
pose a challenge to governments who have not only committed to WTO 
agreements but also under bilateral and regional trade and investment 
treaties. A degree of clarity may yet arise when the outcomes of these 
pending cases are known. Until then, negotiators of FTAs and BITs will 
no doubt have to have their eye on these complaints while carrying on 
with their ongoing treaty negotiation activities. 
 
Another factor of importance is the outcome of the TPP negotiations as its 
treatment of the above issues could not only have an immediate impact on 
its signatories (several of which are Asian), but potentially other countries, 
if TPP is used as a ‘template’ for future negotiations (particularly with 
regard to health regulatory issues) bilaterally or multilaterally. 
 
For policy-makers and treaty negotiators the price of other trade and/or 
non-economic (e.g. political) benefits must be weighed seriously against 
the above implications. 
 
